A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder.
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Orvepitant (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 15 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Apr 2009 New trial record